Plenty of room for a game changerin the HCV market, despite...

Plenty of room for a game changer
in the HCV market, despite latest breakthrough drugs
such as Sovaldi:

"Some private insurers and Medicaid programs are restricting Sovaldi to the sickest patients, at least for now; they're hoping that new competitors, set for approval later this year, will help spur some price competition. That strategy may work, but then again, other hep C drug developers have suggested that they're not interested in a pricing war. All of them, of course, want to profit off their own R&D efforts.

But some payers intend to play hardball. Top PBMExpress Scripts has said that it will compare the various drugs in the new crop of hep C treatments--and will exclude products if they're not considered to be worth their prices."


http://www.fiercepharma.com/story/top-payer-group-shoots-down-gileads-hep-c-drug-sovaldi-price/2014-05-21